BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Active Biotech’s Laquinimod Fails to Meet Primary Endpoint in Phase II Trial

  The primary endpoint of brain atrophy as defined by PBVC from baseline to week 48, was not met after daily oral doses with 0.6 mg laquinimod.

  December 1, 2017

   · 

  2 min read
• Business

  Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results

  During fiscal year 2017, the company advanced a number of strategic initiatives to optimize its manufacturing operations and to secure additional locations for the biologic source of KLH.

  December 1, 2017

   · 

  14 min read
• Business

  BlueRock Therapeutics Announces Appointment of Derek Hei, Ph.D. as Senior VP, Manufacturing, Quality and Regulatory

  Dr. Hei brings to BlueRock over twenty years of experience developing breakthrough cell and gene therapies from research through clinical trials.

  December 1, 2017

   · 

  2 min read
• Business

  EMD Serono Appoints Zhen Su, M.D., MBA to CMO, North America

  In this role, Dr. Su will collaborate with the local and global medical, development and regulatory teams to drive the progress of EMD Serono’s portfolio and pipeline, as well as enhance scientific leadership in the US.

  December 1, 2017

   · 

  3 min read
• Business

  Bayer and the Broad Institute of MIT and Harvard Expand Partnership to Advance Drug Discovery Research for Novel Cancer Treatments

  Bayer and the Broad Institute of MIT and Harvard announced today that they have extended their multi-disciplinary research partnership by an additional five years, to develop and advance novel cancer treatments.

  December 1, 2017

   · 

  5 min read
• Business

  Daiichi Sankyo and Translational Sciences Conclude Agreement, After Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization

  Daiichi Sankyo will return all rights to develop and commercialize Translational Sciences’ investigational thrombus dissolving agent, TS23, after a successful Phase 1a clinical trial.

  December 1, 2017

   · 

  2 min read
• Biotech Beach

  Impact Biomedicines Closes First Tranche of Oberland Capital Financing Following FDA Meeting

  Impact Biomedicines announced that it has achieved the first milestone in the Company’s previously disclosed $90 million financing with Oberland Capital, triggering the closing on the first tranche of $20 million.

  December 1, 2017

   · 

  4 min read
• Pharm Country

  Tauriga Sciences Announces Board Approval for Up to $150,000 Share Buy-Back Program Effective Immediately

  The Company expects the purchases to be made from time to time in the open market or in unsolicited privately negotiated transactions, and that such purchases are expected to be funded from available cash on hand under Florida law.

  December 1, 2017

   · 

  3 min read
• Policy

  Life Sciences Ontario Launches Blueprint for Coordinated Ontario Life Sciences Strategy

  The document is endorsed by leading provincial and national life sciences, health, and economic organizations.

  December 1, 2017

   · 

  2 min read
• BioMidwest

  Promega HiBiT Protein Tagging System Named a 2017 Top 10 Innovation

  Promega Corporation announced today that its HiBiT Protein Tagging System has been listed as a 2017 Top 10 Innovation by life science publication The Scientist.

  December 1, 2017

   · 

  3 min read